Kamil Drucis

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

Jean‐Jacques Grob, Mayur M. Amonkar, Bogusława Karaszewska et al. · The Lancet Oncology · 2015 · 262 citations

Medicine, Oncology, Pharmacology +11

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Brigitte Dréno, John F Thompson, B. Mark Smithers et al. · The Lancet Oncology · 2018 · 198 citations · Full text

Medicine, Immunology, Oncology +14

3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · European Journal of Cancer · 2015 · 79 citations

Medicine, Oncology, Pharmacotherapy +12

Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma

Caroline Robert, Bogusława Karaszewska, Jacob Schachter et al. · Annals of Oncology · 2016 · 73 citations · Full text

Medicine, Oncology, Pharmacotherapy +15